News Archive

Lesley Curtis, PhD, member in the Duke Clinical Research Institute (DCRI), chief of the Department of Population Health Sciences and professor in the Duke School of Medicine Departments of Population Health Sciences and Medicine was selected to receive the QCOR Outstanding Lifetime Achievement Award by the American Heart Association’s Council on Quality of Care and Outcomes Research (QCOR).

One of the premier scientific meetings of the year with over 10,000 clinicians and researchers in attendance, the 2023 American Heart Association Scientific Sessions focused on the latest research and insights to improve cardiovascular health. This year’s event was held in Philadelphia, Nov. 10-13. The DCRI was represented in poster sessions, moderated digital poster sessions, debates, simulations, learning labs and main stage presentations.

Researchers from the Duke Clinical Research Institute (DCRI) were once again named to Clarivate's Most Highly Cited Scientists list.

By randomizing 10,000 adult patients, ARTEMIS will evaluate the effects of a study medicine versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.

An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health. The drug, ceftobiprole, showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus bacterial infections. If approved by the FDA, ceftobiprole could provide another line of defense against a common and often deadly bacterial infection.

When it comes to COVID-19 testing and vaccination, not all Hispanic populations respond the same.

Explore how the integration of digital tools and consumer-oriented approaches in clinical trials can enhance participant diversity and recruitment efficiency while addressing challenges in equity, ethics, and security.

Cardiovascular disease is the number one killer of people in the United States and worldwide. Yet physicians often do not prescribe evidence-based medicines that could change those statistics.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no clinical benefit to taking fluticasone furoate for treatment of mild-to-moderate COVID-19 symptoms.

CardioHealth Alliance is announcing a new project sponsored by Amgen aimed at assessing and gathering data regarding how to improve quality of care among patients hospitalized for ASCVD. This work, referred to as the “Test to Treat” project, will be led by cardiovascular disease prevention specialist and DCRI faculty member Neha Pagidipati, MD, MPH.